论文部分内容阅读
采用链霉亲和素过氧化酶免疫组织化学方法 (S -P法 )检测 30例初发成人急性髓系白血病(AML)患者的骨髓细胞bcl - 2蛋白表达 .结果 :( 1)AML患者骨髓细胞中bcl - 2蛋白阳性表达率为( 55 12± 2 3 78) % ( 19%～ 93% ) ,显著高于正常对照 (P <0 0 1) . ( 2 )AML按FAB分型各亚型间比较 :bcl- 2蛋白表达在M1,M2 型阳性率较高 ( 60 58± 19 0 5) % ;M3 型则较低 ( 2 1 50± 6 2 2 ) % ;M4 ,M5型最高( 69 64± 14 96) % . ( 3)经标准诱导治疗后 ,完全缓解 (CR)组的bcl- 2蛋白表达显著低于未缓解 (NR)组 (P <0 0 5) .提示 :bcl- 2蛋白在AML细胞中呈高表达 ,并为白血病化疗耐药的预后指标之一 .
Streptavidin peroxidase immunohistochemistry (S-P method) was used to detect bcl-2 protein expression in myeloid cells in 30 patients with primary acute adult myeloid leukemia (AML). Results: (1) Marrow marrow of AML patients The positive expression rate of bcl-2 protein in cells was (55 12 ± 2 3 78) % (19%-93%), which was significantly higher than that of normal controls (P <0 01). (2) AML was classified by FAB Inter-model comparison: bcl-2 protein expression was higher in M1 and M2 (60 58± 19 0 5) %; M 3 type was lower (2 1 50± 62 2) %; M4 and M5 were the highest ( 69 64± 14 96) % . (3) After standard induction therapy, bcl-2 protein expression in the complete remission (CR) group was significantly lower than that in the non-remission (NR) group (P < 0.05). Tip: bcl- 2 The protein is highly expressed in AML cells and is one of the prognostic indicators of leukemia chemotherapy resistance.